These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7161195)

  • 1. Biological properties of ristocetin-ps-aglycone.
    Nielsen RV; Hyldig-Nielsen F; Jacobsen K
    J Antibiot (Tokyo); 1982 Nov; 35(11):1561-4. PubMed ID: 7161195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin.
    Coller BS; Gralnick HR
    J Clin Invest; 1977 Aug; 60(2):302-12. PubMed ID: 17620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-glycosylthioureido aglyco-ristocetins without platelet aggregation activity.
    Sztaricskai F; Pintér G; Röth E; Herczegh P; Kardos S; Rozgonyi F; Boda Z
    J Antibiot (Tokyo); 2007 Aug; 60(8):529-33. PubMed ID: 17827665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Destruction of the platelet aggregating activity of ristocetin A.
    Kuwahara S; Chambers WT
    Experientia; 1978 Apr; 34(4):532-4. PubMed ID: 565300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of biologically active ristocetin derivatives: replacements of the 1'-amino group.
    Herrin TR; Thomas AM; Perun TJ; Mao JC; Fesik SW
    J Med Chem; 1985 Sep; 28(9):1371-5. PubMed ID: 4032439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
    Pintér G; Bereczki I; Batta G; Otvös R; Sztaricskai F; Roth E; Ostorházi E; Rozgonyi F; Naesens L; Szarvas M; Boda Z; Herczegh P
    Bioorg Med Chem Lett; 2010 May; 20(9):2713-7. PubMed ID: 20381348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy.
    Borawski J; Rydzewski A; Mazerska M; Kalinowski M; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 1996 Dec; 11(12):2444-8. PubMed ID: 9017620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and properties of derivatives at the amino group of ristocetin aglycone.
    Kobrin MB; Katrukha HS; Fedorova GB
    J Antibiot (Tokyo); 1989 Sep; 42(9):1441-2. PubMed ID: 2507496
    [No Abstract]   [Full Text] [Related]  

  • 9. [Assessment of speed of an anti-platelet effect after two different doses of acetylsalicylic acid by flocculation].
    Malý M; Vojácek J; Hadacová I; Mates M; Hájek P; Durdil V
    Vnitr Lek; 2004 Jun; 50(6):428-33. PubMed ID: 15346635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired ristocetin aggregation in myeloma due to binding of the aggregating agent by monoclonal protein--presentation of a case.
    László E; Péterfy M; Puskás E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(6):852-6. PubMed ID: 2453415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings: Variations in quantitative ristocetin platelet aggregation (RPA) with time after platelet rich plasma (PRP) preparation: association with alteration in pH.
    Coller BS; Gralnick HR
    Thromb Diath Haemorrh; 1975 Nov; 34(2):581-2. PubMed ID: 809
    [No Abstract]   [Full Text] [Related]  

  • 12. Ristocetin- and thrombin-induced platelet aggregation at physiological shear rates: differential roles for GPIb and GPIIb-IIIa receptor.
    Kasirer-Friede A; Frojmovic MM
    Thromb Haemost; 1998 Sep; 80(3):428-36. PubMed ID: 9759623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PS-5, a new beta-lactam antibiotic. II. Antimicrobial activity.
    Sakamoto M; Iguchi H; Okamura K; Hori S; Fukagawa Y; Ishikura T; Lein J
    J Antibiot (Tokyo); 1979 Apr; 32(4):272-9. PubMed ID: 38238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a new mode of defective ristocetin-induced platelet aggregation.
    Baugh RF; Hougie C
    J Lab Clin Med; 1981 Jun; 97(6):864-80. PubMed ID: 6971912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antibacterial activity in vitro of ristocetin, kanamycin and farmiglucine].
    Pierangeli L; Vellucci A; Tallarida G; Donati G
    Boll Soc Ital Biol Sper; 1964 Dec; 40(24):1662-3. PubMed ID: 5877895
    [No Abstract]   [Full Text] [Related]  

  • 16. [A conjugate of ristomycin A ristosaminylaglycon-polymyxin B: the spectrum of its antimicrobial action and its membranolytic activity].
    Polin AN; Petrykina ZM; Katrukha GS
    Antibiot Khimioter; 1997; 42(5):24-8. PubMed ID: 9254583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impairment of ristocetin-induced platelet aggregation in patients with infective endocarditis.
    Matsumoto M; Murakami H; Matsushima T; Tamura J; Sadakata H; Narahara N; Sawamura M; Naruse T; Tsuchiya J
    J Int Med Res; 1994; 22(1):63-6. PubMed ID: 8187946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibacterial activity of ristocetin, kanamycin and farmiglucine in association with other antibiotics].
    Donati G; Pierangeli L; Vellucci A; Tallarida G
    Boll Soc Ital Biol Sper; 1964 Dec; 40(24):1663-4. PubMed ID: 5877896
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor.
    Allain JP; Cooper HA; Wagner RH; Brinkhous KM
    J Lab Clin Med; 1975 Feb; 85(2):318-28. PubMed ID: 234499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study of the possible interactions between human platelets and the antibiotic MDL-507 (teicoplanin).
    Porta M; Ricchetti I
    Int J Clin Pharmacol Ther Toxicol; 1986 Dec; 24(12):661-4. PubMed ID: 2950065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.